Cellectis Licenses Genomic Engineering Technology to Novartis | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cellectis today announced the licensing of certain patents to Novartis covering certain uses of homologous recombination.

The deal grants the Swiss-based pharmaceutical firm patents for the family WO 90/11354. The technology belongs to the Pasteur Institute and Cellectis owns exclusive rights to them.

The technology allows researchers to introduce new characteristics into genomes.

Financial terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.